Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1476-5551
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1 ; day:12 ; month:3 ; year:2018 ; pages:1-5
Leukemia ; (12.3.2018), 1-5

Urheber
Garderet, Laurent
Beteiligte Personen und Organisationen
Laubach, Jacob P.
Stoppa, Anne-Marie
Hari, Parameswaran
Cavo, Michele
Ludwig, Heinz
Mateos, María-Victoria
Luptakova, Katarina
Lin, Jianchang
Yung, Godwin
Velde, Helgi van de
Berg, Deborah
Moreau, Philippe
Richardson, Paul G.
SpringerLink (Online service)

DOI
10.1038/s41375-018-0091-3
URN
urn:nbn:de:1111-20180527838
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:37 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Garderet, Laurent
  • Laubach, Jacob P.
  • Stoppa, Anne-Marie
  • Hari, Parameswaran
  • Cavo, Michele
  • Ludwig, Heinz
  • Mateos, María-Victoria
  • Luptakova, Katarina
  • Lin, Jianchang
  • Yung, Godwin
  • Velde, Helgi van de
  • Berg, Deborah
  • Moreau, Philippe
  • Richardson, Paul G.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease

Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease

Verbundene Objekte